Longboard Pharmaceuticals has recently announced the initiation of the global Phase 3 DEEp SEA study.

Novo Nordisk announced on its official website the primary results of a Phase 2a clinical trial for its investigational drug monlunabant (previously known as INV-202).

Sanofi announced its entry into the nuclear medicine field through an exclusive licensing agreement with RadioMedix and Orano Med to jointly develop next-generation RLT for rare cancers.

AstraZeneca submitted a market application for the injectable drug Tremelimumab.

Nurix Therapeutics unveiled promising data from its Phase 1a/1b clinical trial of NX-5948 at the 12th International Workshop on Waldenstrom's Macroglobulinemia.

In the development of antibody-drug conjugates (ADCs), selecting an appropriate linker is a critical factor that determines the efficacy and safety of the final product.

A recent review in the journal Nature Reviews Clinical Oncology has explored new therapeutic approaches for multiple myeloma (MM) targeting cell membrane proteins.

Hiro-LS, PatSnap's biopharmaceutical AI model, integrates the proprietary PharmaGPT, a large-scale AI model with 70 billion parameters.

the Danish pharmaceutical company Zealand Pharma announced clinical Phase 1 data for its long-acting amylin analogue, Petrelintide, which is being studied for weight management.

Amylin is a pancreatic peptide consisting of 37 amino acids that is co-stored and co-secreted with insulin in response to nutrient intake.

On September 19, 2024, the NMPA accepted Hengrui Pharmaceutical's marketing authorization application for the Class 1 new drug Retlirafusp-α Injection (SHR-1701).

Recently, Innovent Biologics announced promising clinical results for their potential first-in-class dual-specific antibody fusion protein targeting PD-1 and IL-2 (IBI363).